Clinical trials: Nutrition Disorder
Overweight, Diabetes Mellitus Type 2 in Obese
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187 It will be conducted in three parts, as described below: Part I will be the Single…
- Trial name
- NCT01874366
- Testing
- P11187
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Overweight and Obesity
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss…
- Trial name
- NCT02041195
- Testing
- Setmelanotide
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Overweight and Obesity
Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals
Evaluate the effect of Synbiotic 365 (Version 5 and 7) on body composition in overweight and obese individuals as measured by change in body mass index (BMI) and the percentage of body fat from Day 0 to Day 84 when compared to…
- Trial name
- Obesity (NCT04611477)
- Testing
- Rice Hulk, Synbiotic365 Ver 5, Synbiotic365 Ver 7
- Where
- India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Obesity
The Effect of Betahistine on Body Weight in Obese Subjects
The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects.
- Trial name
- NCT00409305
- Testing
- Betahistine, Dietary counseling
- Where
- 19 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- OBEcure Ltd.
Obesity, NAFLD
Study of NGM395 in Adult Participants
Study of NGM395 in adult participants.
- Trial name
- NCT04187339
- Testing
- NGM395
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Malnutrition
An Observational Study to Assess Malnutrition Risk
This is a prospective, observational study for assessing malnutrition risk and its characteristics among children aged 1 to 5 living in under-resourced communities in Colombia.
- Trial name
- NCT06709001
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Abbott Nutrition
Obesity
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects
The purpose of this study is to evaluate the safety, tolerability and effect on body weight and other obesity-related factors of different doses of BMS-830216, compared to placebo.
- Trial name
- NCT00909766
- Testing
- BMS-830216
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
HIV Infections, HIV Wasting Syndrome
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal…
- Trial name
- NCT00002157
- Testing
- Thalidomide
- Where
- United States
- Sponsor
- Celgene Corporation
Pregnancy, Obesity
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05872022
- Testing
- No Intervention
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 728 people
- Sponsor
- Novo Nordisk A/S
Healthy, Obesity
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous…
- Trial name
- NCT07693231
- Testing
- BI 3034701
- Where
- 3 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine.
- Trial name
- NCT00471172
- Testing
- Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)
- Where
- 12 sites in United States
- Volunteers
- 350 people
- Sponsor
- Pfizer
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
- Trial name
- NCT06885021
- Testing
- HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeks
- Volunteers
- 780 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population
The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a…
- Trial name
- NCT06569355
- Testing
- VCT220
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity, Overweight
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo.
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee
- Trial name
- AMAZE 6 (NCT07509307)
- Testing
- NNC0487-0111
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Respiratory Insufficiency, Obesity Hypoventilation Syndrome
Juno Perth Clinical Trial
This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat respiratory insufficiency, respiratory…
- Conditions
- Respiratory Insufficiency, Obesity Hypoventilation Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Disease
- Trial name
- NCT02317042
- Testing
- Juno
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- ResMed
Fatty Liver, Non-Alcoholic Steatohepatitis
A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic…
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Trial name
- Aramchol_005 (NCT02279524)
- Testing
- Aramchol
- Where
- 78 sites in United States, Chile and 9 more
- Volunteers
- 247 people
- Sponsor
- Galmed Research and Development, Ltd.
Obesity
A Study of BGM0504 in Participants With Obesity
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
- Trial name
- NCT06911203
- Testing
- BGM0504, Tirzepatide
- Where
- China
- Volunteers
- 96 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Obesity
Safety and Effectiveness of Orbera365™ Intragastric Balloon System
This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss.
- Trial name
- Orbera365 (NCT07062094)
- Testing
- Intragastric Balloon
- Where
- 4 sites in Czechia, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.